Key points are not available for this paper at this time.
Our findings indicate that the currently used rifampin dosage in the therapy of TB is too low. In our murine TB model a rifampin dosage of 80 mg/kg/d enabled a significant reduction in therapy duration without adverse effects.
Steenwinkel et al. (Sat,) studied this question.